Congenital Hyperinsulinism Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Congenital Hyperinsulinism (CHI) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Congenital Hyperinsulinism in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Congenital Hyperinsulinism from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2028
Congenital Hyperinsulinism - Disease Understanding and Treatment Algorithm
Congenital Hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma. Congenital Hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Congenital Hyperinsulinism, refers to a clinically, genetically and morphologically heterogeneous group of disorders associated with dysregulated Insulin secretion.
The DelveInsight Congenital Hyperinsulinism market report gives the thorough understanding of the Congenital Hyperinsulinism by including details such as disease Introduction, Pancreatic β‑Cell Physiology, Glucose Metabolism and Insulin Secretion, Types of Congenital Hyperinsulinism, causes, Molecular basis, clinical presentation and symptoms, Pathophysiology, Genetics of Congenital Hyperinsulinism, Diagnosis, and Differential diagnosis. It also provides treatment algorithms and treatment guidelines for Congenital Hyperinsulinism in the US, Europe, and Japan.
Congenital Hyperinsulinism Epidemiology
The Congenital Hyperinsulinism epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Population of Congenital Hyperinsulinism, Total Diagnosed Prevalent Population of Congenital Hyperinsulinism, Type specific Diagnosed Prevalence of Congenital Hyperinsulinism, Sub-type specific Diagnosed Prevalence of Congenital Hyperinsulinism) scenario of Congenital Hyperinsulinism in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
A study titled as “Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders” by Charles A. Stanley concluded that Hypoglycemia is present at birth, but recognition is often delayed because symptoms of hypoglycemia in neonates can be subtle, and low concentrations of plasma glucose are often confused with the commonly observed transitional HI of normal neonates. This transitional neonatal HI may reflect persistence of a lower glucose threshold for Insulin release that is necessary to maintain fetal growth. Furthermore, The HI associated with HNF4A and HNF1a mutations may be transient in early infancy or may persist into later childhood and is usually responsive to diazoxide. According to DelveInsight, the total number of prevalent population of Congenital Hyperinsulinism will change from the study period 2017-2028.
Congenital Hyperinsulinism Drug Chapters
This segment of the Congenital Hyperinsulinism report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Congenital Hyperinsulinism, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the Incident population of Congenital Hyperinsulinism & awareness of the disease. The overall dynamics of Congenital Hyperinsulinism market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Zealand Pharma, Rezolute, Xeris Pharmaceuticals and some others, will significantly increase the market during the forecast period (2019-2028).
Congenital Hyperinsulinism Market Outlook
The Congenital Hyperinsulinism market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Congenital Hyperinsulinism in 7MM is expected to change from 2019-2028.
Congenital Hyperinsulinism Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Congenital Hyperinsulinism such as Dasiglucagon (Zealand Pharma), RZ358 (Rezolute), CSI-Glucagon (Continuous Subcutaneous Glucagon Infusion) (Xeris Pharmaceuticals) and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Congenital Hyperinsulinism market.
Congenital Hyperinsulinism Report Insights
• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Congenital Hyperinsulinism Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Congenital Hyperinsulinism Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Congenital Hyperinsulinism market
• Organize sales and marketing efforts by identifying the best opportunities for Congenital Hyperinsulinism market
• To understand the future market competition in the Congenital Hyperinsulinism market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook